Clinical trials: Chronic Glomerulonephritis
Chronic Kidney Diseases, Diabetes
KidneYou - Innovative Digital Therapy
The aim of the study is to assess the improvement of health in patients affected by CKD when they are exposed to non-pharmacological treatment strategies as nutritional program (NP), physical activity program (PA) and mindfulness…
- Conditions
- Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis
- Trial name
- NCT05286632
- Testing
- KidneYou APP
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Advice Pharma Group srl
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics.
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure
- Trial name
- FSGS (NCT02194582)
- Where
- United States
- Volunteers
- 2,050 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Nephrotic Syndrome
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Trial name
- NCT05599815
- Testing
- ADX-629
- Where
- 11 sites in United States
- Sponsor
- Aldeyra Therapeutics, Inc.
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
IgA Nephropathy, Chronic Kidney Disease
Steroids and Azathioprine in Advanced IgAN
Some years ago the investigators designed a randomised trial to prospectively evaluate whether adding low-dose azathioprine (1.5 mg/kg/day for six months) to steroids (methylprednisolone 1 g i.v.
- Trial name
- NCT01392833
- Testing
- methylprednisolone, azathioprine, prednisone
- Volunteers
- 46 people
- Sponsor
- A. Manzoni Hospital
IgA Nephropathy, Immunoglobulin A Nephropathy
A Study of Zigakibart in Adults With IgA Nephropathy
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
- Trial name
- NCT05852938
- Testing
- BION-1301
- Where
- 200 sites in United States, Argentina and 21 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Proteinuria, Kidney Injury
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease
This study will evaluate in patients with kidney disease, the role that certain inflammatory and immune mediators play in promoting kidney damage.
- Conditions
- Proteinuria, Kidney Injury, Chronic Kidney Disease
- Trial name
- NCT01156428
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- The Rogosin Institute
IgA Nephropathy
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16…
- Trial name
- NefXtend (NCT06712407)
- Testing
- TARPEYO®
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Calliditas Therapeutics AB
Focal Segmental Glomerulosclerosis, Guillain-Barre Syndrome
Regional Citrate Anticoagulation in Plasma Exchange Treatment
The investigators want to compare the efficacy of plasma exchange treatment with using two different citrates ( 4% and 15% ) as anticoagulants in plasma exchange treatment.
- Trial name
- NCT01370200
- Testing
- plasma exchange treatment
- Where
- Slovenia
- Volunteers
- 140 people
- Sponsor
- University Medical Centre Ljubljana
Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects suffering from chronic kidney disease and from healthy volunteers.
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)
- Trial name
- BIOMIS-Nefro (NCT04689074)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 2 sites in Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Lupus Nephritis, IgA Nephropathy
The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
- Trial name
- NCT02493101
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Focal Segmental Glomerulosclerosis
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk factor for end stage renal failure.
- Trial name
- TRANSLATE (NCT02585804)
- Testing
- Dapagliflozin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
IGA Nephropathy
Mycophenolate Mofetil for IgA Nephropathy
IgA nephropathy (IgAN) is the commonest primary glomerulonephritis worldwide. In Hong Kong, IgAN accounts for approximately 30% of all primary glomerular diseases, and a significant proportion of young patients (< 50 years of…
- Trial name
- NCT00863252
- Testing
- mycophenolate mofetil, angiotensin blockade
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Chronic Kidney Diseases
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental…
- Trial name
- JUSTICE (NCT05237388)
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
ADPKD, Glomerulonephritis
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.
- Trial name
- NCT00345137
- Testing
- Ng-monomethyl-L-arginine (drug)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Cancer
Wormwood in Chronic Progressive Disorders With Reduced Appetite
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.
- Trial name
- NCT01126931
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Freiburg
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb